Project Grant R01DA062450
- The National Institute on Drug Abuse awarded Rutgers, The State University of New Jersey (RBHS-School of Nursing) $515,211 on July 1, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to conduct research on post-overdose treatment gaps and prevention opportunities in high-risk youth. The research examines nonfatal drug overdoses in adolescents and young adults to identify barriers to behavioral health treatment connection and to generate evidence for tailored prevention...
- The National Institute on Drug Abuse awarded Rutgers The State University of New Jersey (doing business as RBHS-School of Nursing) $2,107,844 on September 15, 2025, under the Drug Use and Addiction Research Programs (CFDA 93.279) to conduct a longitudinal mixed-methods study of nicotine pouch adoption and use patterns among U.S. adults. The research combines a nationally representative longitudinal survey with qualitative interviews to examine who uses nicotine pouches, reasons for adoption,...
- The National Institute on Drug Abuse awarded Rutgers The State University of New Jersey, doing business as RBHS-School of Nursing, $1.413 million on July 1, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to develop, refine, and test a telehealth-delivered motivational interviewing intervention for young adults who use electronic nicotine delivery systems (ENDS). The project will develop and test a cessation-induction intervention designed to prompt quit attempts in...
- The National Institute on Drug Abuse awarded New York University $169,489 on March 15, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to support research on estrogenic regulation of neuromodulators and temporal discounting. The research investigates how hormonal fluctuations modulate the neural and molecular mechanisms underlying temporal discounting—the rate at which animals depreciate reward value based on anticipated delay. The project uses high-throughput behavioral...
- The National Institute of Neurological Disorders and Stroke awarded Rutgers The State University of New Jersey (RBHS-School of Nursing) $787,111 on September 5, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to develop and validate a humanized antisense oligonucleotide (ASO) targeting nerve injury-specific long non-coding RNA (NIS) as a non-opioid, non-addictive analgesic for chronic neuropathic pain. The R61 phase includes design, synthesis, and purification of...
- The National Institute on Drug Abuse awarded Rutgers The State University of New Jersey $139,612 on February 1, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to support research integrating artificial intelligence and co-production methods to analyze communications in online substance use disorder recovery groups. Dr. Xiangyu Tao, a postdoctoral associate at the Rutgers Addiction Research Center, will conduct research examining how engagement in online peer support...
- The National Institute on Drug Abuse awarded Drexel University $832,132 on March 1, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to investigate novel circuit mechanisms underlying opioid-induced dopamine elevations in the nucleus accumbens, operating beyond the canonical midbrain dopamine neuron pathway. The research explores how oxycodone enhances dopamine signals through local circuits in the nucleus accumbens, specifically examining the role of GABA and cholinergic...
- The National Institute on Drug Abuse awarded New York University $547,333 on September 1, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to conduct a mixed-methods study identifying state-level implementation strategies for expanding access to extended take-home methadone doses in opioid treatment programs. The award funds a phased R61/R33 project examining how state agencies—including state opioid treatment authorities and Medicaid agencies—are facilitating adoption of...
- The National Institute on Drug Abuse awarded Icahn School of Medicine at Mount Sinai $100,228 on October 8, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to support research on opioid reward mechanisms. The award funds a project investigating the functional role of a novel cortical circuit connecting the dorsal peduncular nucleus to the ventral tegmental area in mediating opioid reward. The research employs barcoded anatomy resolved by sequencing combined with spatial...
- The National Institute on Drug Abuse awarded the University of Rhode Island $186,622 on June 15, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to develop and pilot a stigma-reduction training intervention for registered nurses providing pain care to individuals with opioid use disorder. The award funds the development and pilot evaluation of STAR-RN (Stigma-Reduction Training and Addiction Resources for Registered Nurses), an evidence- and theory-informed intervention...
The National Institute on Drug Abuse awarded Rutgers The State University of New Jersey (doing business as RBHS-School of Nursing) $642,253 on August 15, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to conduct high-precision mapping of sex hormone modulation of reward value computations in opioid addiction. The research addresses disparities in medications for opioid use disorder treatment, which fails in a sizable proportion of patients, particularly female patients who experience higher relapse rates and earlier treatment dropout than males. The project investigates how fluctuating ovarian sex hormones—estradiol and progesterone—modulate dopamine-mediated neural computations, specifically reward prediction error, which the brain uses to learn and update what is valuable and when to take actions that maximize reward. The research tests whether estradiol-related changes in reward value computations heighten reward sensitivity and transiently bias decisions toward high-value options such as those associated with opioid use. Understanding these mechanisms may support development of personalized treatments and improved outcomes for female patients with opioid use disorder. Performance of work occurs in New Jersey. The project period runs from the award date through May 31, 2031. This is a Project Grant, the standard assistance type for NIDA-supported research projects with project periods typically not exceeding five years.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $642.3k | 8/3/26 |